Cormorant Asset Management’s Immune Design Corp. IMDZ Stock Holding History

Cormorant Asset Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-280,500	Closed	-$2.9M	–	63
2017 Q3	$2.9M	Sell	280,500 -56,500	-17%	-$556K	0.51%	43
2017 Q2	$3.29M	Hold	337,000	–	–	0.54%	47
2017 Q1	$2.29M	Sell	337,000 -95,990	-22%	-$555K	0.33%	57
2016 Q4	$2.38M	Hold	432,990	–	–	0.32%	60
2016 Q3	$3.28M	Hold	432,990	–	–	0.36%	62
2016 Q2	$3.53M	Buy	432,990 +243,990	+129%	+$3.04M	0.5%	51
2016 Q1	$2.46M	Hold	189,000	–	–	0.37%	59
2015 Q4	$3.79M	Hold	189,000	–	–	0.45%	52
2015 Q3	$2.31M	Hold	189,000	–	–	0.37%	55
2015 Q2	$3.9M	Buy	189,000 +70,000	+59%	+$1.65M	0.52%	46
2015 Q1	$2.51M	Sell	119,000 -21,000	-15%	-$548K	0.39%	54
2014 Q4	$4.31M	Sell	140,000 -60,000	-30%	-$1.67M	0.66%	38
2014 Q3	$3.53M	Buy	+200,000	New	+$2.53M	0.73%	38

Other funds holding IMDZ

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cormorant Asset Management's IMDZ Position: Q4 2017 in Review

Cormorant Asset Management sold out of Immune Design Corp. (IMDZ) in Q4 2017, closing a stake of 280,500 shares — an estimated $2.9M sold.

Cormorant Asset Management first reported a position in IMDZ in Q3 2014 and held it in 13 quarters. The position peaked at $4.31M in Q4 2014. 76 funds tracked by Wall St. Rank hold IMDZ as of Q4 2017.

Cormorant Asset Management reported no remaining Immune Design Corp. position as of Q4 2017 after selling out during the quarter.
Cormorant Asset Management sold 280,500 Immune Design Corp. shares in Q4 2017, an estimated $2.9M.
Cormorant Asset Management first reported a position in Immune Design Corp. in Q3 2014 and held it in 13 quarters.
Cormorant Asset Management's Immune Design Corp. position peaked at $4.31M in Q4 2014.
76 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2017.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.